Skip to main content

Table 3 Mechanisms of action of drugs currently in Phase 1, Phase 2, and Phase 3 clinical trials (as of February 27, 2014)

From: Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

Unique compounds per MoA (current pipeline 02–27)

Phase 1

Phase 2

Phase 3

Total

Symptomatic for cognition

5

10

10

25

Symptomatic for behavior

2

3

4

9

Disease-modifying small molecule (amyloid-related)

4

5

1

10

Disease-modifying small molecule (tau-related)

3

0

1

4

Disease-modifying small molecule (neuroprotector)

2

19

4

25

Disease-modifying immunotherapy

4

8

3

15

Therapeutic device

2

4

0

6

Stem cells

0

1

0

1

Total

22

50

23

95